Fig. 1 · Structure

Documents & Downloads

NPS-2143 (SB-262470)

Cat. No. A11140 CAS 284035-33-2

CaSR antagonist

NPS-2143 is a selective Ca2+-sensing receptor antagonist, shown to block increases in cytoplasmic Ca2+ concentrations elicited by human Ca2+ receptors expressed in HEK293 cells with an IC50 of 43 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Ca(2+) receptor 43 nM

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.003 nM Displacement of [3H](2-(2-hydroxyphenyl)-6-methyl-5-(2-methylpropyl)-3-(2-phenylethyl)-4(3H)-pyrimidinone) from human calcium receptor expressed in human HEK293 4.0-7 cells by liquid scintillation counting [PMID: 19821575]
HEK293 IC50 0.058 nM Antagonist activity at human calcium receptor expressed in HEK293 4.0-7 cells assessed as inhibition of intracellular calcium release by FLIPR assay [PMID: 19821575]
HEK293 IC50 0.08 μM Inhibitory concentration for the inhibition of intracellular [Ca2+] release in HEK cells by using FLIPR technology [PMID: 15686947]
PC-12 IC50 0.026 μM Antagonist activity at human CaSR expressed in rat PC12 cells transfected with zif promoter/luciferase by reporter gene assay [PMID: 20472433]
TT IC50 0.05 μM Inhibition of intracellular calcium release in human TT cells containing calcium-sensing receptor by FLIPR [PMID: 16216508]

NPS-2143 (SB-262470) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of NPS-2143 (SB-262470) from 3 published references. In vitro models include Y-79 cells; HEK293 cells transfected with the mutant Gln723 CaSR-EGFP.

NPS-2143 (SB-262470) In Vitro Studies

In Y-79 cells, NPS-2143 at 16.5 µM significantly down-regulated p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα expression compared with control. In HEK293 cells transfected with mutant Gln723 CaSR-EGFP, NPS-2143 treatment yielded higher EC50 values than the matched mutant-plus-vehicle control. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Expression of signaling components in Y-79 cells

Cell-based study · Y-79 cells [1]

Y-79 cells were treated with NPS-2143 at 16.5 µM. Expression of p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα was significantly down-regulated compared with the control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
the expression of NF-κB signaling pathway related key genes, p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBαReported result p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα were down-regulated significantly in NPS-2143 treated group compared with control group in Y-79 cells. **P < 0.05 vs. control.[1]

Literature-Reported Treatment Conditions

Treatment concentration
16.5 µM
Reported limits
Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations

Compound reported in the paper: NPS-2143

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > NPS-2143 suppressed the proliferation of Y-79 cells and induced the apoptosis of Y-79 cells (S44); Results > NPS-2143 affected the malignant behaviors of Y-79 cells through regulating NF-κB signaling pathway (S55); Fig. 2 legend (S83)

the expression of NF-κB signaling pathway related key genes, p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα: the expression of NF-κB signaling pathway related key genes, p-P65 NF-κB, P65 NF-κB, p-IκBα and IκBα; comparator: control group — Fig. 2 legend (S83)

Calcium response in transfected HEK293 cells

Cell-based study · HEK293 cells transfected with the mutant Gln723 CaSR-EGFP [2]

HEK293 cells transfected with mutant Gln723 CaSR-EGFP were incubated with NPS-2143 at 20nM, 40nM, and 80nM. EC50 values were 2.79 ±0.19 mM, 3.97 ±0.10 mM, and 4.56 ±0.09 mM, respectively, compared with 1.94 ±0.07 mM for Gln723 (m) plus vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
EC50 (ie, Ca2+o concentration required for 50% of the maximal response)EC50 2.79 ±0.19 mM; 3.97 ±0.10 mM; 4.56 ±0.09 mM[2]

Literature-Reported Treatment Conditions

Treatment concentration
20nM, 40nM, and 80nM
Exposure duration
one hour
Method
incubated
Vehicle
15% aqueous solution of 2-hydroxypropyl-β-cyclodextrin
Co-treatment
Other interventions in this design: mutant CaSR-EGFP construct; Lipofectamine Plus; Ca2+o 0mM to 10mM. Compound effect isolated by the comparison: Gln723 (m) + vehicle.
Methods and source locations

Compound reported in the paper: NPS-2143

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In vitro assessment of NPS 2143 on the functional responses of the Leu723Gln mutant CaSR (S1, S3, S5, S9); Materials and Methods > In vivo administration of NPS 2143 to Nuf mice (S13, S14); Figure 2. legend (S48, S50, S53); Table 1. (T1.h1, T1.h2, T1.r2, T1.r3, T1.r4, T1.r5)

EC50 (ie, Ca2+o concentration required for 50% of the maximal response): EC50 (ie, Ca2+o concentration required for 50% of the maximal response); comparator: Gln723 (m) + vehicle — Materials and Methods > In vitro assessment of NPS 2143 on the functional responses of the Leu723Gln mutant CaSR (S9); Table 1. (T1.h1, T1.h2, T1.r2, T1.r3, T1.r4, T1.r5)

NPS-2143 (SB-262470) In Vivo Studies

In Nuf/+ mice, NPS-2143 administered as a single intraperitoneal bolus at 30 mg/kg yielded plasma adjusted calcium of 2.21 ± 0.06 mmol/L versus 1.88 ± 0.04 mmol/L with vehicle only. In male BALB/C nude mice bearing subcutaneous U87‐MG cells, intraperitoneal NPS-2143 at 80 μM/kg remarkably suppressed glioma tissue volume and weight in the comparison with corn oil. [2,3]

Adjusted plasma calcium in Nuf/+ mice

Animal study · Nuf/+; inbred 102/H background; n = 13 [2]

Nuf/+ mice received a single intraperitoneal bolus at 30 mg/kg. At 1 hour after administration, plasma adjusted calcium was 2.21 ± 0.06 mmol/L with treatment versus 1.88 ± 0.04 mmol/L with vehicle only.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Plasma adjusted calciumplasma adjusted calcium 2.21 ± 0.06 mmol/L[2]

Conditions shared by the study groups

Route
ip injection
Treatment course
A single bolus; at 1 hour after administration
Vehicle
15% aqueous solution of 2-hydroxypropyl-β-cyclodextrin
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NPS-2143 30 mg/kgVehicle OnlyDrug: 2.21 ± 0.06 mmol/L; Vehicle Only: 1.88 ± 0.04 mmol/L; P < .001[2]
NPS-2143 30 mg/kg
Model: Nuf/+; inbred 102/H background; n = 13
Methods and source locations

Compound reported in the paper: NPS-2143

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > In vivo administration of NPS 2143 to Nuf mice (S10, S13, S15); Figure 3. legend (S54); Table 2. legend (S58, S61); Table 2. (T2.h2, T2.h3, T2.r11, T2.r12)

Plasma adjusted calcium: Plasma adjusted calcium; comparator: Vehicle Only — Figure 3. legend (S54); Table 2. legend (S61); Table 2. (T2.h2, T2.h3, T2.r11)

NPS-2143 30 mg/kg · Materials and Methods > In vivo administration of NPS 2143 to Nuf mice (S13, S15); Table 2. legend (S58, S61); Table 2. (T2.h2, T2.h3, T2.r11)

Glioma tissue volume and weight in nude mice

Animal study · Male BALB/C nude mice; U87‐MG cells were subcutaneously injected into the flank of nude mice [3]

Male BALB/C nude mice bearing subcutaneous U87‐MG cells received NPS-2143 at 80 μM/kg intraperitoneally. In the comparison with corn oil, NPS-2143 remarkably suppressed glioma tissue volume and weight.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumour volumeReported result NPS‐2143 remarkably suppressed the volume and weight of glioma tissues[3]

Conditions shared by the study groups

Route
intraperitoneally injected
Treatment course
every 2 days three times
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
NPS-2143 80 μM/kgcontrol group (corn oil)NPS‐2143 remarkably suppressed the volume and weight of glioma tissues[3]
NPS-2143 80 μM/kg
Model: Male BALB/C nude mice; U87‐MG cells were subcutaneously injected into the flank of nude mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: NPS-2143

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Nude mice xenograft (S43, S46, S47, S48); RESULTS > NPS‐2143 suppress glioma growth in a xenograft mouse model (S102, S103)

tumour volume: tumour volume; comparator: control group (corn oil) — MATERIALS AND METHODS > Nude mice xenograft (S47); RESULTS > NPS‐2143 suppress glioma growth in a xenograft mouse model (S103)

NPS-2143 80 μM/kg · MATERIALS AND METHODS > Nude mice xenograft (S48); RESULTS > NPS‐2143 suppress glioma growth in a xenograft mouse model (S102, S103)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 284035-33-2
Applications CaSR antagonist
Formula C24H25ClN2O2
Molecular Weight 408.9
Synonyms SB262470
SMILES
CC(C)(CC1=CC2=CC=CC=C2C=C1)NC[C@H](COC3=C(C(=CC=C3)Cl)C#N)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (193.18 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NPS-2143 (SB-262470) Research References

  1. [1] Zhang C, Yu T, Sun G, et al. NPS-2143 suppresses malignant phenotypes of retinoblastoma cells involved in regulating NF-κB pathway. Sci Rep (2025). PMID: 40346093 DOI: 10.1038/s41598-025-00783-z Source material
  2. [2] Hannan FM, Walls GV, Babinsky VN, et al. The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1). Endocrinology (2015). PMID: 26052899 DOI: 10.1210/en.2015-1269 Source material
  3. [3] Nie JL, Li Q, Yin HT, et al. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway. J Cell Mol Med (2024). PMID: 38509759 DOI: 10.1111/jcmm.18221 Source material

Added to your cart

View Cart Checkout
Loading...